Introduction
============

Remote ischemic preconditioning (RIPC) is defined as brief transient episodes of ischemia followed by a prolonged sustained episode of ischemia and reperfusion in the heart. It was first described by Murry et al in 1986, when they showed that brief ischemic episodes in dogs by the experimental occlusion of the left coronary artery reduced infarct extension caused by the occlusion of the circumflex artery and subsequent reperfusion.[@b1-ijgm-11-175] It was observed that these induced ischemic periods followed by reperfusion promote cardioprotection in situations in which this prolonged ischemic event is expected, like in cardiac surgeries, transplants or even percutaneous coronary angioplasty.[@b2-ijgm-11-175]

Kadkhodaee et al reported protective effects in the kidney by pre- and post- conditioning in ischemic situations and induced reperfusion.[@b3-ijgm-11-175] Besides all other risk factors, patients on hemodialysis have a common complication from the procedure associated with myocardial ischemia. With the prolonged decrease of oxygen supply, a left ventricular dysfunction can be observed in the long run, resulting in cardiac insufficiency and an increase in mortality.[@b4-ijgm-11-175]

A recent study reveals that conventional hemodialysis, besides being associated with endothelial injury, oxidative stress and high inflammatory activity, can induce microcirculation injury with consequent critical ischemia and tissue damages during the procedure.[@b4-ijgm-11-175], [@b5-ijgm-11-175]

It is known that cardiac troponin I (cTnI) and cardiac troponin T (cTnT) levels are usually elevated and related to mortality in such cases. A recent meta-analysis concluded that the elevation of cTnI and cTnT represents a 2.64- and 1.74-fold increase in mortality, respectively.[@b6-ijgm-11-175] The aim of this study was to analyze the RIPC effect in myocardial injury by means of the measurement of cTnI in patients with chronic kidney disease on hemodialysis.

Patients and methods
====================

Study design
------------

This is a randomized clinical trial. Patients were divided into two groups: experiment and control. Randomization was performed according to the list generated by the website [www.randomizatiom.com](http://www.randomizatiom.com), which was accessed only by the nurse in charge of the dialysis. Researchers remained blinded as to which group each patient belonged to. Patients on medications for the treatment of pre-existing diseases were not washed out.

Hemodialysis sessions were set to 3:30 hours, with blood flow of 300 mL/min, dialysate flow of 500 mL/min, sodium concentration of 140 mEq/L and bicarbonate of 34 mEq/L. The ultrafiltration value was defined according to the individual need of each patient. Written informed consent was obtained from each participant included in this study; this study and its protocol were conducted in accordance with the Declaration of Helsinki, and the study was approved by the Faculdade de Medicina do ABC Ethics Committee (CAAE number 45920015.5.0000.0082).

Study interventions
-------------------

The ischemic preconditioning consisted of a 5-minute interruption of the brachial blood flow using a Tycos sphygmomanometer (Welch Allyn, Skaneateles Falls, NY, USA) inflated to 200 mmHg or until the distal blood flow was interrupted; subsequent deflation followed with the same rest period, and the procedure was repeated twice, totaling 30 minutes of intervention. The contralateral arm was chosen, next to the functioning arteriovenous fistula, and in the absence of the fistula, the right arm was used. The intervention occurred in the beginning of the dialysis session. The intervention group underwent three consecutive sessions of RIPC, whereas control group underwent none.

Interesting outcomes
--------------------

The primary outcome was the decrease in ultrasensitive cTnI level when intervention and control groups were compared. The secondary outcome was mortality by any cause at time points 30 and 90 days, hospitalization due to cardiovascular event defined as acute coronary syndrome, pulmonary thromboembolism or cerebrovascular accident.

Variables of interest
---------------------

The analysis of biochemical markers was carried out using blood samples collected at 2 and 7 days prior to the allocation, in the beginning of the first hemodialysis session, after the initial allocation.

Plasma cTnI levels were measured by ELISA assay, and their cutoff values were defined according to the constructed calibration curve. Values above the 99th percentile were considered altered.

For dialysis adequacy, the values of single-pool Kt/V and the urea reduction ratio (URR) were considered adequate if they were ≥1.2 and 65%, respectively.

The analysis of the inflammatory markers was performed using the ELISA method. Cutoff values were set on a method-by-method basis according to each used kit, following each manufacturer's instructions.

Statistical analysis
--------------------

This was a 40-patient pilot study. The sample was divided into two groups: 20 in the control group and 20 in the intervention group.

Qualitative variables were presented with absolute and relative frequencies and analyzed by the chi-square test. Shapiro--Wilk test was used to verify the normality of quantitative variables. As the distribution was not normal, median values, along with the respective 95% confidence intervals, were used. Quantitative variable between groups were analyzed with the Mann--Whitney test, and Wilcoxon test was applied to verify if there were differences in the collections before and after each moment, confidence interval was 95%. Data Analysis and Statistical Software for Professionals (Stata), version 11.0, was the statistical package used.

Results
=======

The mean age in the control group was 63.9 years (SD±15.8), and in the intervention group it was 52.1 years (SD±21.5). All of the patients from both groups suffered from systemic hypertension. Diabetes was present in 60.8% of the patients in the intervention group and in 65.2% in the control group.

[Table 1](#t1-ijgm-11-175){ref-type="table"} shows the characterization of the samples, taking parameters like gender, Kt/V, hemoglobin and ferritin into consideration.

[Table 2](#t2-ijgm-11-175){ref-type="table"} shows the mean values of troponin pre- and post-dialysis in control and intervention groups. Interestingly, between the moments of pre- and post-dialysis the significance value was \<0.05 (*p*\<0.05) according to the Wilcoxon test, demonstrating that the RIPC did not have the expected effect.

In [Table 3](#t3-ijgm-11-175){ref-type="table"} it can be observed that there were no significant variations in the point estimation for urea, URR and troponin between control and intervention groups.

Discussion
==========

It is known that chronic kidney disease patients on hemodialysis, even those without acute coronary disease, have high serum levels of troponin.

So far, very few management strategies have been proposed to reduce myocardial damage caused by hemodialysis. Remote ischemic preconditioning is one of the propositions.[@b7-ijgm-11-175],[@b8-ijgm-11-175]

Troponin is the biomarker of choice for the analysis of myocardial ischemia due to the fact that it is an enzyme specific to the cardiac muscle that plays an important role in the muscle contraction process; moreover, it practically has no relation with skeletal muscles. Most of the studies use troponin T (TnT) as a marker; studies using troponin I (TnI) are not only few but also short-term, with a small number of patients included.[@b9-ijgm-11-175]

A 2012 study on the predictive value of troponin in patients on hemodialysis revealed a strong discrepancy between TnT and TnI values, which can be explained by their molecular mechanisms, like structure, molecular weight and half-life.[@b10-ijgm-11-175] Besides, the kinetics of enzyme release in the circulation after the alterations in myocyte membrane permeability can be different, and there is a divergence between the clearance of both enzymes Once released in the circulation, TnI becomes more susceptible to modifications owing to phosphorylation, oxidation and proteolysis.

Factors like aggressive ultrafiltration and intradialytic hypotension are associated with the aggravation of the myocardial ischemic condition during a hemodialysis session owing to the significant alterations in the coronary flow. Repeated injuries induced by ischemia followed by reperfusion cause alterations in motility and loss of contractility, which may lead to myocardial fibrosis and irreversible left ventricular systolic dysfunction.[@b11-ijgm-11-175]

Burton et al showed that nearly 50% of patients on hemodialysis developed alterations in regional myocardial motility, and also that the mortality rate among these patients increased in the subsequent 12 months.[@b4-ijgm-11-175]

No RIPC benefits, performed in three consecutive hemodialysis sessions in this study, could be observed. However, Park et al reported its beneficial effects in 12 consecutive hemodialysis sessions, when a decrease in TnT levels could be observed.[@b12-ijgm-11-175]

This study faced some limitations. First, the number of sessions was lower than in other published studies, and it is not surely known how many interventions are necessary to obtain such benefits. The presence of diabetes is a positive predictive factor for higher cardiovascular mortality. Moreover, coronary collateral circulation in diabetic patients is higher due to the presence of ischemia, a factor that may be responsible for the lower response rate in patients undergoing RIPC. The studied sample included a diabetic population of \>50%.[@b5-ijgm-11-175], [@b13-ijgm-11-175]

In sum, in the model of three consecutive hemodialysis sessions, no significant reduction in ultrasensitive troponin I concentrations could be observed when remote ischemic preconditioning was applied.
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###### 

Characterization of samples according to the studied groups

  Studied Groups     Groups                 *p*[\*](#tfn2-ijgm-11-175){ref-type="table-fn"}   
  ------------------ ---------------------- ------------------------------------------------- -----------------------------------------------------
  Gender, n (%)                                                                               
   Female            9.0 (40.9)             8.0 (34.8)                                        0.672[\*](#tfn2-ijgm-11-175){ref-type="table-fn"}
   Male              13.0 (59.1)            15.0 (65.2)                                       
  Kt/V               1.5 (1.1--1.5)         1.5 (1.1--1.6)                                    0.846[\*\*](#tfn3-ijgm-11-175){ref-type="table-fn"}
  Hemoglobin, g/dL   10.6 (10.4--11.5)      11.1 (10.8--11.6)                                 0.190[\*\*](#tfn3-ijgm-11-175){ref-type="table-fn"}
  Albumin, g/dL      3.8 (3.6--4.0)         4.0 (3.9--4.1)                                    0.010[\*\*](#tfn3-ijgm-11-175){ref-type="table-fn"}
  Ferritin, ug/L     560.0 (364.9--563.5)   375.0 (278.1--391.7)                              0.076[\*\*](#tfn3-ijgm-11-175){ref-type="table-fn"}

**Notes:** Confidence interval of 95% shown in brackets;

chi-square;

Mann--Whitney test.

###### 

Point estimation (interval estimation) of troponin concentration according to the moments in control and intervention groups

  cTn          Control                Intervention                                                                 
  ------------ ---------------------- ---------------------- ------- ---------------------- ---------------------- -------
  Troponin 1   0.010 (0.006--0.016)   0.009 (0.006--0.023)   0.631   0.007 (0.006--0.012)   0.007 (0.006--0.011)   0.152
  Troponin 2   0.010 (0.006--0.014)   0.011 (0.006--0.018)   0.634   0.009 (0.006--0.017)   0.006 (0.006--0.014)   0.987
  Troponin 3   0.011 (0.006--0.018)   0.013 (0.007--0.027)   0.024   0.007 (0.006--0.018)   0.006 (0.006--0.009)   0.136

**Notes:** Values expressed in median (confidence interval of 95%);

Wilcoxon test.

###### 

Point estimation of concentration variation of urea, troponin and urea reduction ratio between groups

  Markers                                                            Groups                       *p*[\*\*](#tfn8-ijgm-11-175){ref-type="table-fn"}   
  ------------------------------------------------------------------ ---------------------------- --------------------------------------------------- -------
  Urea[\*](#tfn7-ijgm-11-175){ref-type="table-fn"}                   63.50 (36.86--89.35)         75.75 (35.86--104.52)                               0.672
  Troponin[\*](#tfn7-ijgm-11-175){ref-type="table-fn"}               --0.001 (--0.0064--0.0021)   0.001 (--0.0014--0.0014)                            0.441
  Urea reduction ratio[\*](#tfn7-ijgm-11-175){ref-type="table-fn"}   --0.650 (--8.074--11.427)    4.500 (--8.090--13.901)                             0.503

**Notes:** Values expressed in median (confidence interval of 95%);

variation between the first and last collection;

Wilcoxon test.
